Clinical

Dataset Information

0

Real-world study of the efficacy and safety of bevacizumab for first-line and post-first-line treatment of advanced RAS mutated colorectal cancer

ABSTRACT: Interventions: experimental group:chemotherapy combined with bevacizumab Primary outcome(s): Progression-Free Survival;Overall Survival Study Design: Sequential

DISEASE(S): Colorectal Cancer

PROVIDER: 2702727 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Unknown Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study.
| S-EPMC10232683 | biostudies-literature
Unknown Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients-Real-World Evidence.
| S-EPMC9032972 | biostudies-literature
Unknown Real-World Experience of First-Line Osimertinib in EGFR Mutated Non-Small Cell Lung Cancers from a Tertiary Cancer Center, India.
| S-EPMC12747758 | biostudies-literature
Unknown Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice.
| S-EPMC6700318 | biostudies-literature
Unknown Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data.
| S-EPMC9392819 | biostudies-literature
Unknown First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial.
| S-EPMC10427431 | biostudies-literature
Unknown A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy.
| S-EPMC8593121 | biostudies-literature
Transcriptomics First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial [RNA-Seq]
2023-07-05 | GSE235919 | GEO
Transcriptomics First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial [scRNA-Seq]
2023-07-05 | GSE235917 | GEO
Clinical Medical Records Based Real-World Study of Cetuximab in Combination with FOLFIRI Regimen as First-Line Chemotherapy and Subsequent Cetuximab-based Maintenance Therapy for the Maintenance Treatment of Patients with RAS and BRAF Wild-Type Unresectable Metastatic Colorectal Cancer
| 2701129 | ecrin-mdr-crc